Arbutus Biopharma Corp.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Arbutus Biopharma Corp.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
/ 
Frequently asked questions
To buy Arbutus Biopharma Corp. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Arbutus Biopharma Corp. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Arbutus Biopharma Corp. is ABUS:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Arbutus Biopharma Corp. has its primary listing on NASDAQ (Small cap). You can trade Arbutus Biopharma Corp. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Arbutus Biopharma Corp. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Arbutus Biopharma Corp. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Arbutus Biopharma Corp..